Gow CH - Search Results

1

Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer.

Yang CH, Shih JY, Chen KC, Yu CJ, Yang TY, Lin CP, Su WP, Gow CH, Hsu C, Chang GC, Yang PC. Yang CH, et al. Among authors: gow ch. Cancer. 2006 Oct 15;107(8):1873-82. doi: 10.1002/cncr.22220. Cancer. 2006. PMID: 16989002 Free article.

2

EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer.

Shih JY, Gow CH, Yang PC. Shih JY, et al. Among authors: gow ch. N Engl J Med. 2005 Jul 14;353(2):207-8. doi: 10.1056/NEJM200507143530217. N Engl J Med. 2005. PMID: 16014893 No abstract available.

3

Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer.

Shih JY, Gow CH, Yu CJ, Yang CH, Chang YL, Tsai MF, Hsu YC, Chen KY, Su WP, Yang PC. Shih JY, et al. Among authors: gow ch. Int J Cancer. 2006 Feb 15;118(4):963-9. doi: 10.1002/ijc.21458. Int J Cancer. 2006. PMID: 16152581

4

Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R.

Gow CH, Shih JY, Chang YL, Yu CJ. Gow CH, et al. PLoS Med. 2005 Sep;2(9):e269. doi: 10.1371/journal.pmed.0020269. Epub 2005 Sep 27. PLoS Med. 2005. PMID: 16173832 Free PMC article. No abstract available.

5

Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response.

Gow CH, Chien CR, Chang YL, Chiu YH, Kuo SH, Shih JY, Chang YC, Yu CJ, Yang CH, Yang PC. Gow CH, et al. Clin Cancer Res. 2008 Jan 1;14(1):162-8. doi: 10.1158/1078-0432.CCR-07-1468. Clin Cancer Res. 2008. PMID: 18172267

6

First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer.

Wu JY, Yu CJ, Yang CH, Wu SG, Chiu YH, Gow CH, Chang YC, Hsu YC, Wei PF, Shih JY, Yang PC. Wu JY, et al. Among authors: gow ch. Am J Respir Crit Care Med. 2008 Oct 15;178(8):847-53. doi: 10.1164/rccm.200803-389OC. Epub 2008 Jun 26. Am J Respir Crit Care Med. 2008. PMID: 18583573

7

Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response.

Wu JY, Wu SG, Yang CH, Gow CH, Chang YL, Yu CJ, Shih JY, Yang PC. Wu JY, et al. Among authors: gow ch. Clin Cancer Res. 2008 Aug 1;14(15):4877-82. doi: 10.1158/1078-0432.CCR-07-5123. Clin Cancer Res. 2008. PMID: 18676761

8

Multidriver mutation analysis in pulmonary mucinous adenocarcinoma in Taiwan: identification of a rare CD74-NRG1 translocation case.

Gow CH, Wu SG, Chang YL, Shih JY. Gow CH, et al. Med Oncol. 2014 Jul;31(7):34. doi: 10.1007/s12032-014-0034-4. Epub 2014 Jun 10. Med Oncol. 2014. PMID: 24913807

9

Discordant HER2 Exon 20 Mutation Status Determines a Differential Sensitivity to Afatinib.

Gow CH, Liao WY, Liu YN, Shih JY. Gow CH, et al. J Thorac Oncol. 2015 Jul;10(7):e58-60. doi: 10.1097/JTO.0000000000000518. J Thorac Oncol. 2015. PMID: 26134234 Free article. No abstract available.

10

A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population.

Gow CH, Hsieh MS, Wu SG, Shih JY. Gow CH, et al. Lung Cancer. 2017 Jan;103:82-89. doi: 10.1016/j.lungcan.2016.12.001. Epub 2016 Dec 5. Lung Cancer. 2017. PMID: 28024701

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

35 results

Search Page

Filters